MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Acta scientific neurology · 2025

Dopaminergic Homeostatic Therapy (DHT™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS®) Screening.

Lewandrowski Kai-Uwe, Bowirrat Abdalla, Pinhasov Albert, Sharafshah Alireza, Gold Mark S, Fuehrlein Brian, Elman Igor, Dennen Catherine, Thanos Panayotis K, Hanna Colin, Sipple Daniel, Baron David, Martire Gianni, Modestino Edward J, Jafari Nicole, Zeine Foojan, Sunder Keerthy, Lewandrowski Alexander Pl, Badgaiyan Rajendra D, Khalsa Jag, Pollack Aryeh, Fiorelli Rossano Kepler Alvim, Schmidt Sergio, Fliegelman Chynna, Lorio Morgan P, Makale Milan T, Blum Kenneth

СтатьяПеревод пока не подготовлен

Аннотация

In spite of the ongoing exquisite work of a multitude of researchers worldwide including governmental institutions like the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and for example in the United States the FDA Medication Assisted Therapy (MAT) embracing Opioid Replacement Therapy (ORT) in 2022, 111,000 people prematurely died from opioid induced overdose. It is estimated that if treatment stays as usual by 2025 the death rate will increase to 165,00.Therefore, we are encouraging the scientific and clinical community to at least consider our "out of the box" thinking whereby we are proposing a new paradigm shift involving the " dopaminergic homeostatic modeling approach and Genetic screening to early identify preaddiction. In this novel approach following detoxification from for example powerful opioids, the patient is administered the validated RDSQ29 to access potential psychological profiling of Reward Deficiency Syndrome (RDS); obtain a cheek cell sample of the patient and perform genetic screening utilizing the Genetic Addiction Risk Severity (GARS); analyze mRNA to identify specific protein deficits/surfeits based on the measured reward genes involved in the Brain Reward Cascade (BRC); produce a customized pro-dopamine regulator (KB220) guided by GARS resulting polymorphisms; objectively employ the mRNA profiling assessment every week during the treatment phase to determine improvement; each treatment program could add on at their choice, for example, cognitive behavioral therapy, brain spotting, trauma therapy, electrotherapy (h-wave device to reduce pain, subluxation repair etc.) mindfulness, exercise, neuromodulation (PrTMS) amongst other modalities. The utilization of this model could prove beneficial to both substance and non-substance behavioral addictions (e. g. gaming). WC261 .

Для цитирования: Lewandrowski Kai-Uwe, Bowirrat Abdalla, Pinhasov Albert, Sharafshah Alireza, Gold Mark S, Fuehrlein Brian, Elman Igor, Dennen Catherine, Thanos Panayotis K, Hanna Colin, Sipple Daniel, Baron David, Martire Gianni, Modestino Edward J, Jafari Nicole, Zeine Foojan, Sunder Keerthy, Lewandrowski Alexander Pl, Badgaiyan Rajendra D, Khalsa Jag, Pollack Aryeh, Fiorelli Rossano Kepler Alvim, Schmidt Sergio, Fliegelman Chynna, Lorio Morgan P, Makale Milan T, Blum Kenneth. Dopaminergic Homeostatic Therapy (DHT™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS®) Screening.. Acta scientific neurology. 2025.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.